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Redox-mediated posttranslational modifications
represent a molecular switch that controls major
mechanisms of cell function. Nitric oxide (NO) can
mediate redox reactions via S-nitrosylation, repre-
senting transfer of an NO group to a critical protein
thiol. NO is known to modulate neurogenesis and
neuronal survival in various brain regions in disparate
neurodegenerative conditions. However, a unifying
molecular mechanism linking these phenomena
remains unknown. Here, we report that S-nitrosyla-
tion of myocyte enhancer factor 2 (MEF2) transcrip-
tion factors acts as a redox switch to inhibit both neu-
rogenesis and neuronal survival. Structure-based
analysis reveals that MEF2 dimerization creates a
pocket, facilitating S-nitrosylation at an evolutionally
conserved cysteine residue in the DNA binding
domain. S-Nitrosylation disrupts MEF2-DNA binding
and transcriptional activity, leading to impaired neu-
rogenesis and survival in vitro and in vivo. Our data
define a molecular switch whereby redox-mediated
posttranslational modification controls both neuro-
genesis and neurodegeneration via a single tran-
scriptional signaling cascade.
INTRODUCTION
Redox modification of cysteine, reminiscent of phosphorylation
and ubiquitination of critical amino acids, regulates protein activ-
ity (Hess et al., 2005). One type of redoxmodification involves re-
action of nitric oxide (NO) with cysteine thiol. In this manner, NO
functions as a signaling molecule influencing multiple targets. In
brain, NO regulates physiologic functions including neural devel-
opment, neurotransmitter release, and synaptic plasticity, butexcess NO promotes neuronal damage in a variety of neurode-
generative disorders (Nakamura et al., 2013). Previously, we
and our colleagues demonstrated that NO reacts with critical
cysteine thiols, termed S-nitrosylation, on various proteins to
modulate their activity (Hess et al., 2005). Recently, we found
that S-nitrosylation of the transcription factor myocyte enhancer
factor 2C (MEF2C) occurs in cell-based Parkinson’s disease
(PD) models, resulting in inhibition of transcriptional activity
and resultant cell death via a PGC1a-mediated pathway
(Ryan et al., 2013). Heretofore, however, it remained unknown
if S-nitrosylation of a common target could molecularly ‘‘switch
off’’ both neurogenesis and neuronal survival. Here, we demon-
strate that S-nitrosylation of MEF2A or MEF2C at an inhibitory
‘‘cysteine switch’’ abrogates DNA binding. This redox reaction
shuts off two distinct transcriptional cascades involved in
neuronal survival and neurogenesis.
MEF2 integrates diverse signals and plays roles in the immune,
muscular, and nervous systems. In brain, we and others have
shown that various MEF2 isoforms modulate neurogenesis and
neuronal survival (Flavell et al., 2006; Li et al., 2008; Mao et al.,
1999; Okamoto et al., 2000, 2002; Shalizi et al., 2006). Here, we
used cerebral ischemia models to study the influence of NO on
MEF2 in neuronal cell death, because both NO and MEF2 have
been previously linked to such damage (Huang et al., 1994; Oka-
moto et al., 2002). Additionally, as a tractable paradigm to study
dysfunctional neurogenesis in the adult nervous system,we used
Alzheimer’s disease (AD) models because NO and MEF2 have
both been implicated in the generation of new neurons (Packer
et al., 2003; Li et al., 2008).
RESULTS
S-Nitrosylation of MEF2 Transcription Factors
To confirm that the consensus motif for nitrosylation on MEF2
(Stamler et al., 1997) can indeed be S-nitrosylated (to form
SNO-MEF2), we initially expressed Myc-tagged MEF2C in
human embryonic kidney (HEK) 293 cells and exposed theCell Reports 8, 217–228, July 10, 2014 ª2014 The Authors 217
Figure 1. MEF2 Is S-Nitrosylated In Vitro
and In Vivo during Neurodegeneration
(A) Excitotoxic NMDA (50 mM) was administered to
cortical neurons in the presence or absence of
NOS inhibitor L-NAME (500 mM). After 30 min,
endogenous SNO-MEF2C was detected by biotin
switch. SNO proteins were precipitated from
neuronal lysates, and SNO-MEF2C was detected
with MEF2C-specific antibody. Quantitative
densitometry is shown above immunoblots.
Values are mean ± SEM (n = 3 independent
experiments, *p < 0.0001 by ANOVA with post hoc
Scheffe´’s test).
(B) SNO-MEF2C in contralateral or ipsilateral
cortex 1 hr after MCA occlusion. Values are
mean ± SEM (n = 3 animals, *p = 0.001 by t test).
(C) SNO-MEF2C in brains fromWT littermates and
Tg2576 AD mice. Values are mean ± SEM (n = 4
animals in each group, *p = 0.001 by t test).
(D) SNO-MEF2C in brain tissues from human
control or AD patients by biotin switch.
See also Figure S1.transfected cells to the physiological NO donors, S-nitrosocys-
teine (SNOC) or nitroso-S-glutathione (GSNO). Using the biotin
switch assay in which biotin is selectively substituted for the
NO moiety of SNO-cysteine residues (Jaffrey et al., 2001), we
found that these NO donors induced S-nitrosylation of MEF2C
(Figure S1A).
Next, we asked if endogenous SNO-MEF2 is increased
in neurodegenerative conditions. We primarily focused on
MEF2C because this isoform is known to predominate in
cerebrocortical neurons, although our findings pertain to all
isoforms (Leifer et al., 1993; Li et al., 2008). Because neuronal
cell death triggered by excessive activation of the N-methyl-D-
aspartate (NMDA)-type glutamate receptor is known to be
mediated, at least in part, by generation of endogenous NO
(Dawson et al., 1991), and MEF2C activity has been shown to
ameliorate such damage (Okamoto et al., 2002), we exposed
cultured rat cerebrocortical neurons to 50 mM NMDA and moni-
tored SNO-MEF2C formation by biotin switch assay. We
observed SNO-MEF2C within 30 min of NMDA application, an
effect blocked by cotreatment with the NO synthase (NOS)
inhibitor L-NG-nitroarginine methyl ester (L-NAME; Figures 1A
and S1B). Because apoptosis does not occur in this paradigm
until the next day, these results imply that MEF2C is S-nitrosy-
lated at an early stage of cell-death signaling (Bonfoco et al.,
1995; Cho et al., 2009). NO-induced neurotoxicity has also
been implicated in in vivo studies, including focal cerebral
ischemia (stroke) (Hara and Snyder, 2007; Huang et al.,
1994). Robust NO production has been observed during the
first few hours of cerebral ischemia in rodent middle cerebral
artery (MCA) occlusion models (Kader et al., 1993; Zhang
et al., 1995). Accordingly, we occluded the right MCA of
mice for 1 hr and observed S-nitrosylation of MEF2C in the
ischemic but not the contralateral cerebral cortex (Figures 1B
and S1C), showing that MEF2C is S-nitrosylated in vivo during
ischemia.
In addition to promoting acute neuronal injury in conditions
such as stroke, excessive NO generation has been observed in218 Cell Reports 8, 217–228, July 10, 2014 ª2014 The Authorschronic neurodegenerative diseases, including human AD brains
(Ferna´ndez-Vizarra et al., 2004; Vodovotz et al., 1996). By biotin
switch assay, we examined brains of Tg2576 mice, an ADmodel
overexpressing amyloid precursor protein (APP) with the Swed-
ish mutation, and in postmortem human AD brains. We found
increased SNO-MEF2C levels in both mouse (Figures 1C and
S1D) and human AD brains but not in controls (Figures 1D
and S1E). Taken together, these findings suggest that MEF2C
is S-nitrosylated in vivo both in acute neurodegenerative condi-
tions such as stroke and in chronic neurodegenerative condi-
tions such as AD.
To determine which cysteine residue(s) is S-nitrosylated on
MEF2C and other MEF2 isoforms, we first performed a top-
down analysis of the protein using an linear trap quadrupole
(LTQ)-Orbitrap-XL mass spectrometry with electron transfer
dissociation (ETD). Exposure to the physiological NO donor
SNOC shifted the MEF2C spectral cluster reflecting S-nitroso-
thiol formation on a single cysteine residue (739.9426 m/z),
whereas expected clusters of MEF2C with two S-nitrosothiols
(741.4986 m/z) or more were not observed. These results
indicate the presence of one S-nitrosylation site on MEF2C
(Figure 2A). To identify that site, we mutated each Cys residue
in MEF2C to Ala and then transfected expression vectors
encoding these mutated forms into HEK293 cells. We exposed
the cells to SNOC and analyzed S-nitrosylated MEF2C by the
biotin switch method. Mutation of Cys39 (C39A) abrogated
formation of SNO-MEF2C, whereas other mutations such as
MEF2C(C41A) did not (Figures 2B and S2A, densitometric
quantification). To confirm S-nitrosylation of Cys39, we em-
ployed a direct biochemical analysis for S-nitrosothiols, as
described previously, by monitoring conversion of 2,3-diamino-
naphthalene (DAN) to 2,3-naphthotriazole (NAT) from immuno-
precipitates of HEK293 cells transfected with wild-type (WT)
or mutant MEF2C(C39A) (Wink et al., 1999). In this assay, the
C39A mutation abolished SNO-MEF2C formation (Figure 2C),
supporting the notion that Cys39 is the primary site of
S-nitrosylation.
Figure 2. S-Nitrosylation of MEF2 at Cys39 in the MADS-Box DNA Binding Domain
(A) Recombinant MEF2C protein was infused into amass spectrometer (LTQ-Orbitrap-XL with ETD) to obtain molecular ion spectra in the presence or absence of
NO donor, 50 mM SNOC (n = 2 independent experiments).
(B) HEK293T cells transfected with WTmyc-tagged MEF2C (WT), MEF2C(C39A), or MEF2C(C41A) were incubated with SNOC. SNO-MEF2C was determined by
biotin switch. SNO proteins were precipitated, and SNO-MEF2C was detected with anti-myc (n = 3 independent experiments; quantification shown in
Figure S2A).
(C) HEK293 cells stably expressing nNOS were transfected with V5-tagged MEF2C (WT) or V5-tagged MEF2C(C39A), and nNOS activated with Ca2+ ionophore
A23187. V5-tagged MEF2C proteins were immunoprecipitated with anti-V5 and subjected to DAN assay. Values are mean ± SEM (n = 3 independent experi-
ments, *p < 0.05 by t test).
(D) Sequence alignment of MADS-box DNA binding domains of MEF2 (human isoforms MEF2A-D; Drosophila D-MEF2). a Helix (bars) and b strands (arrows).
Cys39 S-nitrosylation site (yellow). Residues involved in pocket formation (red).
(E) Cys39 (yellow) is symmetrically located at the hinge between a1 helix and b1 strands in the MEF2 (monomer A in blue, monomer B in green) -DNA (pink)
complex (PDB ID: 1EGW). Right: viewed at 90.
(F) Electrostatic view of MEF2 (negative charge in red, positive charge in blue). Cys39 is present at the bottom of the pocket created by Glu14, Arg17, Ser50, Ser51,
Asn49, Phe21, and Gln18.
See also Figure S2.
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S-Nitrosylation of MEF2 Inhibits DNA Binding and
Transcriptional Activity
Next, we investigated the effect of SNO-MEF2 on transcriptional
activity. We noted that Cys39 is conserved in the N-terminal
MADS domain among all MEF2 family members, and other
MEF2 isoforms can also be S-nitrosylated at this position (Fig-
ures 2D, S2B, and S2C). Because MEF2 dimerizes and binds
to DNA through the MADS domain, we studied the effect that
SNO-MEF2 might exert on dimerization and DNA binding.
The structure of the MEF2/DNA complex has been analyzed
by NMR spectroscopy and X-ray crystallography (Han et al.,
2003, 2005; Santelli and Richmond, 2000). Our analysis of these
structures revealed that Cys39 is located at a hinge region where
the a-helical stretch (a1) turns into a b sheet (b1) (Figures 2D
and 2E). Intriguingly, the electrostatic view demonstrates that
Cys39 is at the bottom of a pocket created by seven amino acids:
Glu14, Arg17, Gln18, Phe21, Asn49, Ser50, and Ser51 (Fig-
ure 2F). These residues are highly conserved throughout the
entire MEF2 family (red in Figure 2D). Additionally, these same
residues are often part of an amino-acid motif facilitating S-nitro-
sylation of a critical Cys residue (Greco et al., 2006; Hao et al.,
2006), suggesting that the pocket may form such a nitrosylation
motif.
To determine whether S-nitrosylation alters MEF2 transcrip-
tional activity, we first used a molecular dynamics approach
to analyze the interaction patterns of Cys39 and SNO-Cys39
residues. Using the crystal structure of the solved MEF2A/DNA
complex (Santelli and Richmond, 2000), we modified the
Cys39 residues to SNO-Cys in both polypeptide chains of the
dimer in silico. In order to determine the geometry and electrical
properties of the NO-substituted side chain of Cys39, we then
performed quantum mechanical calculations. The SNO-Cys
dipeptide (CH3CO-NH-CH[CH2SNO]CO-NH-CH3) was used as
a model molecule for deriving essential force-field parameters
necessary for molecular mechanics modeling. The geometry
of the SNO-Cys dipeptide was optimized using the quantum
mechanical GAMESS program (Schmidt et al., 1993), and the
charges on the dipeptide atoms were determined to reproduce
the quantummechanically derived electrostatic potential around
the entire dipeptide using the RESP method (Bayly et al., 1993)
and R.E.D.III program (Vanquelef et al., 2011). We compared
the resultant atomic charges of the SNO-Cys dipeptide side
chain with the charge distribution of the unmodified Cys residue,
for which molecular mechanical parameters are available in
the AMBER force field (Cornell et al., 1995). Substitution of the
H atom with the NO group in Cys39 replaced the positively
charged single atom with two negatively charged atoms, making
the entire side chain electronegative (Figure 3A). This modifica-
tion should, in theory, substantially affect the interaction of
Cys39, located at the hinge region of the DNA binding domain
(Figures 2D and 2E), with the surrounding residues essential for
MEF2/DNA interaction.
We found that the solved atomic structure shows the Cys39
region has a network of interacting residues that controls orien-
tation of the N-terminal polypeptide arm (composed of residues
1–17), which is involved in DNA binding (Figure 3B). One impor-
tant interaction is a salt bridge between the Arg10 and Asp40
residues located in different chains of the MEF2 dimer. Another220 Cell Reports 8, 217–228, July 10, 2014 ª2014 The Authorsimportant interaction is between Arg10 and Arg17 within a single
polypeptide chain. The importance of this second interaction is
experimentally supported because mutation of Arg17 to Val
has been shown to decrease MEF2-DNA binding activity (Mol-
kentin et al., 1996). We thus obtained a plausible conformation
of SNO-Cys39 by molecular mechanical optimization using
the AMBER program and its parm99 force field (Figure 3B)
(Case et al., 2005; Cornell et al., 1995). This type of -SNO orien-
tation could potentially perturb interactions between Arg17 and
Arg10, thus affecting the strength of the salt bridge between
Arg10 and Asp40. This perturbation, in turn, could dislocate
the position of the MEF2 N-terminal arm from the vicinity of
DNA, thus reducing DNA binding.
To test empirically whether S-nitrosylation of MEF2 impairs
DNA binding, as predicted by the atomic structure and quantum
mechanical considerations, we exposed nuclear extracts of
cortical neurons to NO donor and analyzed DNA binding by elec-
trophoretic mobility shift assay (EMSA) (Krainc et al., 1998; Leifer
et al., 1993). We found that exposure to SNOC decreased MEF2
binding to DNA, with binding specificity documented by super-
shift (Figures 3C and S3A). To determine the contribution of
SNO-Cys39 to this effect, we mutated Cys39 to Ala, translated
the mutant protein MEF2C(C39A) in vitro, and assayed DNA
binding by EMSA (Huang et al., 2000). We observed that mutant
MEF2C(C39A), unlike WT, bound to DNA irrespective of SNOC
exposure (Figure 3D). The fact that SNOC had little if any effect
on MEF2C(C39A)-DNA binding is consistent with the notion
that the action of NO onMEF2C-DNA binding involved S-nitrosy-
lation at Cys39.
To analyze whether this effect of NO leads to a decrease
in MEF2 transcriptional activity, we performed reporter gene
assays in cortical neurons. We transfected neurons with a
MEF2-dependent luciferase reporter and exposed the cells to
SNOC. SNOC significantly attenuated MEF2 activity compared
to control (Figures 3E and S3B). Under these conditions, we
observed no cell death in our cortical cultures (Okamoto et al.,
2002); hence, toxicity cannot account for the decrease in
luciferase reporter activity. Transfection with S-nitrosylation-
resistant MEF2C(C39A) completely abrogated the decrease in
transcriptional activity engendered by SNOC, consistent with
the notion that formation of SNO-Cys39 suppressesMEF2 activ-
ity. We also observed a decrement in MEF2 transcriptional activ-
ity in neurons transfected with inducible NOS; this suppressive
effectwasblockedby cotransfectionwithMEF2C(C39A) (Figures
3F and S3C). Because aberrant NOS expression has been asso-
ciated with neurodegenerative conditions such as AD (Ferna´n-
dez-Vizarra et al., 2004; Vodovotz et al., 1996), we postulated
that impairedMEF2 transcriptional activity resulting fromS-nitro-
sylation could contribute to the neurodegenerative process.
Formation of SNO-MEF2C Contributes to Neuronal Cell
Death Both In Vitro and In Vivo
We next investigated the potential link between SNO-MEF2 and
neurodegeneration. We had previously shown that MEF2C is
not only the predominant MEF2 isoform in the cerebrocortex
but that conditional knockout of this isoform selectively in the
brain results in decreased neuronal cell counts and synapses
in vivo (Leifer et al., 1993; Li et al., 2008). If inactivation of
Figure 3. S-Nitrosylation of MEF2 Impairs Its DNA Binding, Transcriptional, and Prosurvival Activities
(A) Computational structure analysis of S-nitrosylated Cys39. Atomic charge distribution for normal Cys and Cys-NO residues obtained from quantummechanical
calculations (see text). Electrostatic potentials: positive charge (blue) and negative charge (red). Values show excess atomic charge.
(B) Optimization of molecular mechanical geometry to show possible orientation of the Cys-NO side chain in MEF2. Key residues of dimer interface are
highlighted.
(C) EMSA of MEF2/DNA binding activity. Nuclear extracts from cortical neurons were exposed to 50 mM SNOC (n = 3 independent experiments). MEF2/DNA
binding complex (arrow).
(D) EMSA of mutant MEF2/DNA binding activity. In vitro translated MEF2C(C39A) was exposed to SNOC (n = 3 independent experiments).
(E) Effect of NO on MEF2 reporter gene activity. Cortical neurons were transfected with empty vector (pcDNA 3.1) or expression vectors for MEF2C or
MEF2C(C39A), MEF2 luciferase reporter construct, and renilla luciferase vector to control for transfection efficiency. Luciferase activity was measured 4 hr
after 50 mM SNOC exposure. Bars represent mean ± SEM (n = 12 cultures derived from three independent platings, *p < 0.0001 by ANOVA with post hoc
Scheffe´’s test).
(F) Effect of iNOS transfection on endogenous MEF2 reporter gene activity. Cortical neurons were transfected with empty vector (pcDNA 3.1) or expression
vectors for iNOS with or without MEF2C(C39A), and MEF2 luciferase reporter construct plus renilla luciferase; 24 hr after transfection, luciferase activity was
measured. Bars represent mean ± SEM (n = 12 cultures derived from three independent platings, *p < 0.0001 by ANOVA with post hoc Scheffe´’s test).
(G) Effect of MEF2 S-nitrosylation on neuronal apoptosis. Cortical neurons were transfected with control vector, MEF2C, or MEF2C(C39A) plus enhanced green
fluorescent protein (EGFP) vector to identify transfected neurons. Cultures were then exposed to 50 mM SNOC and analyzed 8 hr later. Hoechst DNA dye was
used to assess condensed, apoptotic nuclei. Bars represent mean ± SEM (n = 9 cultures derived from three independent platings, *p < 0.01, **p < 0.05 by ANOVA
with post hoc Scheffe´’s test).
(H) Stereotactic injection of S-nitrosylation-resistant MEF2C(C39A) mutant (LV-C39A) but not WT MEF2C into striatum improved neuronal survival in stroke
penumbra. Values are mean ± SEM of survival index, representing the inverse of the apoptotic ratio for infected versus uninfected neurons for each construct
(nR 4 animals for each condition, *p < 0.05 by ANOVA with post hoc Scheffe´’s test).
See also Figure S3.MEF2C activity via S-nitrosylation contributes to neurotoxicity,
expression of S-nitrosylation-resistant MEF2C(C39A) should
rescue neurons from NO-mediated cell death. To test this
hypothesis, we expressed MEF2C(C39A) in cortical neurons in
culture and then exposed the cells to SNOC. MEF2C(C39A)
significantly ameliorated NO-induced cell death, as assessed
by monitoring apoptotic nuclei (Figure 3G) and cleaved cas-
pase-3 (Figure S3D). In contrast, this protective effect was not
observed following transfection with WT MEF2C, which is sensi-
tive to S-nitrosylation. These results provide evidence that the
known antiapoptotic function of MEF2 (Mao et al., 1999; Oka-
moto et al., 2000, 2002) is abrogated by S-nitrosylation.To investigate the involvement of SNO-MEF2 in neuronal cell
death in vivo, we used the MCA stroke model because we
had observed an increase in SNO-MEF2C in this mouse model
(see Figure 1B, above). We stereotactically injected lentiviral
expression vectors for GFP alone (LV-GFP), WT MEF2C with
GFP (LV-WT), or mutant MEF2(C39A) with GFP (LV-C39A) into
the striatum, representing the penumbral area where neuronal
apoptosis is known to occur after MCA ischemia. We then
induced MCA occlusion and examined apoptotic neurons in in-
fected versus uninfected neurons for each construct 14 hr post-
reperfusion. We observed a significant difference in the survival
index with the various constructs, with mutant MEF2(C39A)Cell Reports 8, 217–228, July 10, 2014 ª2014 The Authors 221
Figure 4. SNO-MEF2-Induced Suppression of Bcl-xL Contributes to NO-Induced Neuronal Cell Death
(A and B)Western blot analysis of Bcl-xL expression. Cell lysates were collected from cerebrocortex of CamKII-Cre/MEF2C conditional knockout mouse brain (A)
and from cultured rat cerebrocortical neurons exposed to 50 mM SNOC (B). NeuN insured equal loading (NeuN antibody is known to recognize multiple bands).
Quantitative densitometry shown below immunoblots. Values are mean ± SEM (n = 3 for each panel, *p < 0.05 by t test).
(C) NO exposure significantly reduces Bcl-xL promoter activity. Cortical neurons were transfected with a luciferase reporter gene controlled by the Bcl-xL
promoter. SNOC (50 mM) was added 4 hr prior to luciferase assay. Bars represent mean ± SEM (n = 12 cultures from three platings, *p < 0.0001 byMann-Whitney
test).
(D) Reporter assays using Bcl-xL luciferase construct cotransfected with nontargeting shRNA (control) or two shRNAs against MEF2C. Bars represent
mean ± SEM (n = 12 cultures derived from three platings, *p < 0.0001 by ANOVA with post hoc Dunnett’s test).
(E) NO decreases association of endogenous MEF2 with endogenous Bcl-xL promoter in cortical neurons. Chromatin immunoprecipitation (ChIP) assay was
performed for two MEF2 binding sites in the Bcl-xL promoter region. ‘‘Negative Control’’ value indicates virtually no binding 2 kb upstream of the two MEF2
consensus sites. Bars represent mean ± SEM (n = 3 independent experiments, *p < 0.0001, **p < 0.05 by ANOVA with post hoc Scheffe´’s test).
(F) Amelioration of NO-induced cell death in neurons expressing Bcl-xL. Neurons transfected with control vector (pCMV-Sport) or Bcl-xL were exposed to 50 mM
SNOC. Bars represent mean ± SEM (n = 11 cultures from three platings, *p < 0.0001, **p < 0.05 by Kruskal-Wallis test).affording neuroprotection (Figures 3H and S3E). These results
support the notion that SNO-MEF2 contributes to neuronal cell
death in vivo because the nonnitrosylatable MEF2C construct,
unlike control vector or WT MEF2C, enhanced neuronal survival
after stroke.
Next, we studied the mechanism whereby SNO-MEF2 pro-
motes neuronal cell death. Initially, we performed a systematic
analysis of the promoter regions of known cell death/survival
genes to look for potential MEF2 binding sites and foundmultiple
such sites on the published Bcl-xL promoter. Mice that are null
for the Bcl-xL gene manifest massive neuronal death. Interest-222 Cell Reports 8, 217–228, July 10, 2014 ª2014 The Authorsingly, we also found that Bcl-xL levels are decreased in the cor-
tex of conditional MEF2C knockoutmice (Figures 4A and S4A) (Li
et al., 2008). Hence, we tested if S-nitrosylation of MEF2 would
decrease Bcl-xL promoter activity and neuronal expression of
Bcl-xL prior to neuronal cell death and found that this was indeed
the case (Figures 4B, 4C, and S4B). Additionally, MEF2C knock-
down by RNA interference (RNAi) (Figure S4C) resulted in a
decrease in Bcl-xL promoter activity (Figure 4D), consistent
with the notion that NO exposure exerted a similar effect via for-
mation of SNO-MEF2C. As further evidence, we found in chro-
matin immunoprecipitation (ChIP) experiments with anti-MEF2,
Figure 5. MEF2A Is Essential for Adult Hip-
pocampal Neurogenesis In Vitro and In Vivo
(A) Effect of nonnitrosylatable MEF2 on transcrip-
tional activity during neurogenesis. NSCs were
transfected in vitro with MEF2 luciferase reporter,
and MEF2A shRNA expression vector, together
with expression plasmids encoding shRNA-resis-
tant MEF2A (MEF2A-R) or shRNA and S-nitro-
sylation-resistant MEF2A [MEF2A(C39A)-R].
MEF2 transcriptional activity was significantly
decreased after MEF2A knockdown; MEF2
activity was restored to control levels by MEF2A-R
expression and above control levels by
MEF2A(C39A)-R. Data are mean ± SEM (n = 15
cultures derived from three platings, *p < 0.001,
**p < 0.01 by ANOVA with post hoc Scheffe´’s test).
(B) Effect of nonnitrosylatable MEF2A on neuro-
genesis. NSCs were transfected as indicated and
induced toward neural lineage for 2 days. TuJ1+
cells decreased after MEF2A knockdown. Neuro-
genesis recovered to control levels with MEF2A-R
expression and above control levels with
MEF2A(C39A)-R. Data are mean ± SEM (n = 15
cultures from three platings, *p < 0.001, **p < 0.01
by ANOVA with post hoc Scheffe´’s test).
(C and D) Decreased neurogenesis in MEF2A KO
mice in vivo. Control and MEF2A KO mice were
injected with BrdU and sacrificed 4 week later.
Coronal sections of dentate gyrus were immuno-
stained for BrdU (red, newly proliferating cells),
NeuN (green, neuron), and S100b (blue, astrocyte)
(C), and stereologically quantified (D). Data are
mean ± SEM (n = 5 animals for each group,
*p < 0.05 by t test). Scale bar, 100 mm.
See also Figure S5.that NO exposure diminished the association of MEF2 to its
cognate sites on the Bcl-xL promoter (Figure 4E). Moreover,
transfection with Bcl-xL ameliorated NO-induced neuronal cell
death (Figures 4F and S4D). Altogether, our findings suggest
that MEF2 transcriptionally activates Bcl-xL to afford neuropro-
tection, whereas S-nitrosylation of MEF2 limits Bcl-xL expres-
sion and thus contributes to NO-induced neuronal cell death.
SNO-MEF2 Disrupts Adult Neurogenesis Both In Vitro
and In Vivo
In several neurodegenerative conditions including AD, in addi-
tion to neuronal cell injury and death, adult neurogenesis is
also affected (Ohab et al., 2006; Winner et al., 2011). Neurogen-
esis normally persists in the adult hippocampus and contributes
to specific types of learning and memory (Ma et al., 2009; Zhao
et al., 2008). Recent studies in animal models have suggestedCell Reports 8, 217–that NO negatively regulates adult neu-
rogenesis in the hippocampus, but the
mechanism for this effect has remained
elusive (Moreno-Lo´pez et al., 2004;
Packer et al., 2003). To investigate the po-
tential effects of NO-related redox regula-
tion of MEF2 on adult neurogenesis, we
performed experiments to determine the
expression and involvement of MEF2family members in this process both in vitro and in vivo. Initially,
we found that MEF2A was the predominant isoform during
neurogenesis in vitro of adult rat hippocampal neural progeni-
tor/stem cells (NSCs) (Figure S5A), so we studied MEF2A as a
representative MEF2 isoform. To begin to elucidate the function
of MEF2A in adult neurogenesis, we used an RNAi approach.
A short hairpin RNA (shRNA) targeted specifically to MEF2A
(sh-MEF2A) efficiently knocked down MEF2A expression
(Figure S5B). The sh-MEF2A also reduced MEF2-dependent
luciferase reporter gene activity in NSCs (Figure 5A). Coexpres-
sion of an RNAi-resistant form of MEF2A (MEF2A-R) rescued
this decrement in MEF2 activity (Figures S5B and 5A). To inves-
tigate whether MEF2A regulates neurogenesis in NSCs, we
transfected sh-MEF2A, allowed neurogenesis to proceed for
2 days (Gage et al., 1995) and then analyzed the number of
cells expressing the early neuronal marker TuJ1. Knockdown228, July 10, 2014 ª2014 The Authors 223
Figure 6. S-Nitrosylation of MEF2A Regulates TLX Expression
(A) L-NAME (200 mM) increased TuJ1+ cells differentiating from NSCs within 2 days of neural induction in vitro. Data are mean ± SEM (n > 80 cells per condition
from three platings, *p < 0.0001 by t test).
(B) Western blot shows L-NAME inhibited S-nitrosylation of MEF2A in NSCs. Biotin switch assay of cell lysates detected SNO-MEF2A (MEF2Amanifests multiple
bands on immunoblots due to phosphorylated and sumoylated forms [Flavell et al., 2006; Shalizi et al., 2006]). Quantitative densitometry above immunoblots.
Values are mean ± SEM (n = 3 independent experiments, *p = 0.001 by t test).
(C) L-NAME increased MEF2 transcriptional activity in NSCs monitored by luciferase reporter assay. Data are mean ± SEM (n = 16 cultures derived from four
platings, *p < 0.05 by Mann-Whitney test).
(D) nNOS RNA-interference augmented MEF2 transcriptional activity. NSCs were transfected with MEF2 luciferase reporter plus control (nontargeting shRNA)
or two independent nNOS shRNA expression plasmids. Data are mean ± SEM (n = 12 cultures from three platings, *p < 0.0001 by ANOVA with post hoc
Dunnett’s test).
(E) LV-GFP, LV-WT MEF2, or LV-C39A was stereotactically injected into the dentate gyrus of Tg2576 AD mice. Neurogenesis was stereologically assessed by
comparison of GFP, NeuN, and EdU triple-positive cells for LV-WT or LT-C39A as a percentage of LV-GFP. Bars represent mean ± SEM (nR 4 animals for each
condition, *p < 0.05 by t test).
(F) Heatmap of MEF2-dependent gene expression with gene ontology analysis. Total RNA from human NSCs transfected with constitutively active MEF2
(MEF2CA) versus vector control (ptd-Tomato) was used for global expression profiling (n = 3 independent platings and transfections).
(G) L-NAME enhanced TLX expression. NSCswere treatedwith L-NAME, and TLX expression analyzed by quantitative immunofluorescence using deconvolution
microscopy. Data are mean ± SEM (n = 100 cells per condition from three platings, *p < 0.0001 by Mann-Whitney test).
(legend continued on next page)
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of MEF2A decreased the generation of TuJ1+ cells (Figure 5B)
without inducing cell death at this stage of development (Fig-
ure S5C). In contrast, MEF2A-R abrogated the decrement in neu-
rogenesis induced by MEF2A knockdown (Figure 5B), making it
unlikely that an off-target effect of RNAi could account for the
defect in neurogenesis.
Next, we utilized MEF2A knockout mice in order to validate
the role of this MEF2 isoform in adult hippocampal neurogenesis
in vivo. 5-Bromodeoxyuridine (BrdU) was injected into the
mice to label hippocampal NSCs. Four weeks later, we exam-
ined differentiation of the labeled NSCs by double staining brain
sections for BrdU plus NeuN, a mature neuronal marker, or
S100b, an astrocytic marker (Figure 5C). We observed a signifi-
cant decrease in NeuN/BrdU double-positive cells and a signifi-
cant increase of S100b/BrdU double-labeled cells (Figure 5D).
Together, these data indicate that MEF2A plays an important
role in adult hippocampal neurogenesis, both in vitro and in vivo,
akin to the role of this family of transcription factors we previously
demonstrated during embryonic neurogenesis in the developing
cerebrocortex (Li et al., 2008).
Concerning themechanism of the effect of endogenous NOon
adult hippocampal neurogenesis, we observed that the NOS
inhibitor L-NAME significantly increased the generation of new
neurons in cultures of NSCs (Figure 6A). We next asked whether
formation of SNO-MEF2A mediated, at least in part, the inhibi-
tory effect of NO on adult neurogenesis. First, we demonstrated
the existence of SNO-MEF2A in cultures of NSCs under resting
conditions (Figures 6B and S6A). Second, we found that
L-NAME or two short hairpin RNAs against neuronal NOS (sh-
nNOS-1 and -2, Figure S6B) increased MEF2 activity (Figures
6C and 6D).
To examine the functional consequences of S-nitrosylation of
MEF2A at the Cys39 residue on adult neurogenesis, we gener-
ated the nonnitrosylatable mutant MEF2A(C39A). Similar to our
findings with MEF2C(C39A), the DNA binding activity of this mu-
tation was not affected by NO. Accordingly, an RNAi-resistant
form of MEF2A(C39A), designated MEF2A(C39A)-R, resulted in
increased MEF2 transcriptional activity compared to MEF2A-R
in NSCs (Figure 5A). In parallel, MEF2A(C39A)-R generated
more neurons from NSCs than MEF2A-R (Figure 5B). These re-
sults support the notion that S-nitrosylation of MEF2A has a
negative impact on neurogenesis from NSCs.
Because we had shown that SNO-MEF2 levels in the brain
were elevated in advanced cases of human AD and in AD
model mice (Figure 1C), and, because neurogenesis is impaired
under these conditions (Winner et al., 2011), we next investigated
the potential role of SNO-MEF2 in disrupting neurogenesis
in vivo. For this purpose, we labeled adult neural progenitors
with 5-ethynyl-20-deoxyuridine (EdU) in 6-month-old Tg2576(H) ChIP analysis of TLX promoter in NSCs treated with L-NAME. MEF2A immun
change over control Ig immunoprecipitation value (mean ± SEM; n = 5 experime
(I) SNO-MEF2 decreased TLX levels. NSCs were transfected with MEF2A shRNA
vector, and TLX expression analyzed by quantitative immunofluorescence. Data
**p < 0.01 by Kruskal-Wallis test).
(J) Schema for action mechanism of SNO-MEF2 isoforms disrupting neurogen
mediated transcriptional switch.
See also Figure S6 and Table S1.AD mice, which are known to manifest impaired neurogenesis
(Winner et al., 2011). We then stereotactically injected lentiviral
vectors expressing GFP alone (LV-GFP) into the left dentate
gyrus as a control, and WT MEF2 with GFP (LV-WT) or mutant
MEF2(C39A) with GFP (LV-C39A) into the right dentate gyrus
to determine if the nonnitrosylatable mutant versus WT MEF2
would rescue neurogenesis in this AD mouse model. The in-
fected progenitors were allowed to differentiate into neurons
for 4 weeks. Although lentivirus can infect many cell types, we
concentrated here on the effect of MEF2 on NSCs by monitoring
cells that were also colabeled with EdU (indicating that the cells
had divided) and also NeuN (indicating that they had subse-
quently become mature neurons). We then stereologically as-
sessed EdU/GFP/NeuN-positive cells and found that mutant
MEF2(C39A) significantly increased neurogenesis compared to
WT (Figure 6E), consistent with the notion that SNO-MEF2 in-
hibits neurogenesis in AD brain.
Next, to investigate the molecular pathway whereby MEF2
transcriptional activity regulates neurogenesis, we performed a
microarray on mRNA isolated from NSCs expressing a constitu-
tively active form of MEF2 (MEF2CA), which enhances overall
MEF2 activity (Molkentin et al., 1996; Okamoto et al., 2002).
Heatmap and gene ontology analysis of the MEF2-regulated
transcripts demonstrated that the most significant enrichment
of genes occurred in pathways involved in nervous system
development and function (Figure 6F; Table S1). Of particular in-
terest, one of these genes was nuclear receptor tailless (TLX).
TLX had been shown previously to be required for neurogenesis
in the adult hippocampus (Zhang et al., 2008). Moreover, we
found an evolutionarily conserved MEF2 binding site in the pro-
moter of TLX (Sharov et al., 2006). When we exposed NSCs in
culture to NOS inhibitor L-NAME, we observed an increase in
TLX levels (Figure 6G). Similarly, we found an increase in TLX
in the dentate gyrus of L-NAME-treatedmice in vivo (Figure S6C).
Importantly, endogenous MEF2A occupied the TLX promoter,
and NOS inhibition enhanced this association (Figures 6H and
S6D). In contrast, RNAi knockdown of MEF2A resulted in dimin-
ished levels of TLX, whereas an RNAi-resistant form of the
MEF2(C39A) mutant increased TLX compared to RNAi-resistant
WT (Figure 6I). These data are consistent with the notion that
MEF2A is a transcriptional regulator of TLX expression and, via
S-nitrosylation of MEF2A, NO may influence TLX levels.
Conservation of SNO-Cys39 in MEF2 Proteins across
Species and Kingdoms
Our structure-based molecular and biochemical studies define a
mechanism whereby MEF2 possesses a pocket surrounding
Cys39 in the MADS DNA binding domain, and S-nitrosylation
of this Cys residue disrupts DNA binding activity and henceoprecipitation was followed by real-time PCR for TLX promoter. Data are fold
nts, *p < 0.05 by t test).
expression vector plus sh-resistant (R) WT or MEF2(C39A) mutant expression
are mean ± SEM (n > 70 cells per condition from three platings, *p < 0.0001,
esis from neural precursor cells and survival of mature neurons via a redox-
Cell Reports 8, 217–228, July 10, 2014 ª2014 The Authors 225
MEF2 transcriptional activity. Interestingly, the MADS domain is
highly conserved in MEF2 proteins across both the plant and
animal kingdoms (Figures S2B and S2C). In particular, Cys39
is perfectly conserved in all MEF2 sequences. Similarly, Arg17,
Gln18, Phe21, and Asn/Ser49, which form the pocket for S-nitro-
sylation of Cys39, are highly conserved across species. Intrigu-
ingly, in parallel withMEF2 regulation of neurogenesis in animals,
similar MADS family genes in plants control floral development
(Ng and Yanofsky, 2001), which is also negatively regulated by
NO (He et al., 2004). In fact, Cys39 of SEP3, an Arabidopsis
MADS family protein, can also be S-nitrosylated (Figure S6E),
tempting one to speculate that the mechanism described here
may be conserved in many plants and animals.
DISCUSSION
Our findings show that redox modification by NO reacting with a
critical cysteine residue of the MEF2 family of transcription fac-
tors acts as a molecular switch to control neurogenesis and
cell death in the mammalian brain. We found that MEF2A en-
hances adult hippocampal neurogenesis in vitro and in vivo,
and S-nitrosylation of MEF2A inhibits this effect, at least in part
via inhibition of the TLX cascade (Figure 6J). S-Nitrosylation of
MEF2A may thus prevent premature differentiation of adult
NSCs, whereas maintaining rests of these cells under physiolog-
ical conditions. In contrast, we demonstrate in mature neurons
that S-nitrosylation of another MEF2 isoform, MEF2C, contrib-
utes to NO-induced cell death in cerebrocortical neurons during
excitotoxic/ischemic insult and in AD model mice, at least in
part by suppressing the antiapoptotic Bcl-xL pathway (Fig-
ure 6J). Interestingly, this pathway is distinct from the antiapop-
totic MEF2C-PGC1a cascade we recently reported to be
affected by S-nitrosylation in human-induced pluripotent stem
cell (iPSC)-derived dopaminergic neurons as models of PD
(Ryan et al., 2013). Taken together, our findings suggest that
distinct MEF2-initiated transcriptional events are both cell type
and context dependent. Moreover, multiple isoforms of MEF2
may well participate in this redox-switching mechanism.
Generation of excessive NO in the brain has been associated
with several acute and chronic human neurodegenerative dis-
eases, tipping the nitrosylation/denitrosylation homeostatic bal-
ance toward increased nitrosylation (Hara and Snyder, 2007; Na-
kamura et al., 2013). Accordingly, we observed increased levels
of SNO-MEF2 in human stroke and AD brains, indicating that
this redox switch is active in human brain. Thus, we find that dys-
regulation of a single transcription factor family via S-nitrosyla-
tion of an evolutionally conserved Cys can adversely impact
both neuronal cell survival and adult neurogenesis, providing a
commonmechanism for prior empirical observations associated
with increased NO in these neurodegenerative conditions.
Although additional aberrant nitrosylation reactions may also
contribute to these effects (Nakamura et al., 2013), the fact
that a single Cys residue in a single family of transcription factors
plays a role in both neurodegeneration and neurogenesis points
to potential evolutionary as well as therapeutic consequences.
Consideration of the temporal expression of NO, and hence of
SNO-MEF2 formation, may also have important implications for
neuronal cell death and neurogenesis in various disease states.226 Cell Reports 8, 217–228, July 10, 2014 ª2014 The AuthorsFor example, during an acute stroke, NO levels are initially high,
associated with the onset of neuronal cell death, but then quickly
fall, prior to the onset of increased neurogenesis, which occurs
several days after stroke (Huang et al., 1994; Ohab et al.,
2006). In AD, there is progressive generation of Ab oligomers,
which induce NO, coinciding with increasing neuronal cell death.
Additionally, most reports suggest that neurogenesis decreases
as AD progresses (Winner et al., 2011), again coinciding with
increased Ab production and consequent generation of NO.
Hence, the time course of SNO-MEF2 generation may help
explain these phenomena, at least in part.
Moreover, we also relate our results, showing the relation of
SNO-MEF2 to neuronal cell death and dysregulated neurogene-
sis, to findings in the human brain. Specifically, to determine
whether the levels of SNO-MEF2 in human diseased brains are
potentially important, we used a published technique to calcu-
late the ratio of SNO-MEF2 (determined by biotin switch assay)
to total MEF2 (from immunoblots) (Uehara et al., 2006; Cho
et al., 2009). This ratio in human neurodegenerative brain was
comparable to that encountered in our cell-based and animal
models of disease (Figure S6F), consistent with the notion
that pathophysiologically relevant amounts of SNO-MEF2 are
present in human AD brains. Intriguingly, a large genome-wide
association study (GWAS) showed that the MEF2C locus is
associated with AD (Lambert et al., 2013). This finding raises
the possibility that formation of SNO-MEF2, by inhibiting physi-
ological function, may lower the threshold for or even mimic
the effect of genetic alteration (Nakamura et al., 2013). Addition-
ally, our results suggest that SNO-MEF2 may serve as a
biomarker for AD as well as other neurodegenerative conditions.
Moreover, in mouse models of disease in vivo, the nonnitrosylat-
able MEF2(C39A) mutant construct rescued neurons from
apoptotic cell death and improved neurogenesis. In this light,
the pocket surrounding Cys39 on MEF2 may be a potential
target for small molecules that could protect this residue from
aberrant S-nitrosylation; such protection from redox-related re-
actions on this transcription factor may prove to be a useful ther-
apeutic intervention for a variety of neurodegenerative disorders.
EXPERIMENTAL PROCEDURES
Plasmids and Lentiviral Vectors
Bcl-xL-promoter luciferase reporter was provided by Gabriel Nunez (Univer-
sity of Michigan) (Grillot et al., 1997). SEP3 cDNA was provided by Martin
F. Yanofsky (UCSD). High-titer lentiviral constructs (1010 transducing
units/ml) for in vivo injection were generated at the Viral Core of the Salk Insti-
tute for Biological Studies. For details on plasmids and constructs, see the
Supplemental Experimental Procedures.
Cell Culture and Analysis
Human embryonic kidney (HEK) 293T, HEK293 cells stably expressing
neuronal NOS, cerebrocortical neurons, and adult NSCs were cultured as
previously described (Gage et al., 1995; Palmer et al., 1997; Okamoto et al.,
2002; Uehara et al., 2006). For details on assays for apoptosis and cell differ-
entiation, see the Supplemental Experimental Procedures.
In Vivo Mouse Models and Analysis
The intraluminal filament model of middle cerebral artery (MCA) occlusion
(stroke) was used as described previously (Gu et al., 2002; Satoh et al.,
2006). We analyzed SNO-MEF2 formation 1 hr after occlusion, and cell death
1 day after a 90 min occlusion. As an ADmodel, Tg2576 mice were utilized. To
assess the effect of MEF2A on adult neurogenesis, 4- to 6-month-old male
MEF2A KO or WT littermate mice were used. For details of lentiviral injection,
and analysis of apoptosis, neuronal differentiation, and human brain tissues,
see the Supplemental Experimental Procedures.
Analysis of S-Nitrosylation of MEF2
The biotin switch and DAN assays were performed as previously described
(Gu et al., 2002; Jaffrey and Snyder, 2001; Nakamura et al., 2010; Wink
et al., 1999; Yao et al., 2004). For top-down mass spectrometry analysis of
MEF2C, an LTQ-Orbitrap-XL mass spectrometer with ETD was used. For de-
tails of each analysis, see the Supplemental Experimental Procedures.
Geometry Optimization of the S-Nitrosylated MEF2-DNA Complex
For quantum mechanical calculations of the NO-modified cysteine residue, a
molecular model was constructed using the GAMESS program for molecular
dynamics (Schmidt et al., 1993), the RESPmethod (Bayly et al., 1993), R.E.D.III
program (Vanquelef et al., 2011), AMBER, a classical molecular mechanical
program (Case et al., 2005), and its force field (Cornell et al., 1995). For details,
see the Supplemental Experimental Procedures.
Statistical Analysis
Population distributions of the data were examined by the D’Agostino-Pearson
omnibus normality test. If the data did not show a normal distribution, nonpara-
metric tests (Mann-Whitney and Kruskal-Wallis) were used for single compar-
isons and for multiple comparisons, respectively. Otherwise, a two-tailed
Student’s t test was applied for single comparisons and an ANOVA with a
Scheffe´’s or Dunnett’s post hoc test was used formultiple comparisons. All ex-
periments were performed in a blinded fashion. Sample sizes were based on
power analyses performed using our prior data. Statistical significance was
a priori set at a p value <0.05.
Other standard methods, including EMSA, ChIP, and microarray profiling,
are described in the Supplemental Experimental Procedures.
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